With shares of Wal-Mart (NYSE:WMT) trading around $80, is WMT an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock�� MovementWal-Mart operates retail stores in various formats around the world. The company aims to price items at the lowest price every day. Wal-Mart operates in three business segments: the Walmart U.S. segment, the Walmart international segment, and the Sam�� Club segment. It manages retail stores, restaurants, discount stores, supermarkets, super centers, hypermarkets, warehouse clubs, apparel stores, Sam�� Clubs, neighborhood markets, and other small formats, as well as Walmart.com and SamsClub.com. Through its retail channels, Wal-Mart is able to provide a variety of products and services at affordable prices to consumers and companies worldwide.
Wal-Mart executives are feeling the heat from an investigation by the U.S. Department of Justice over possible violations of the Foreign Corrupt Policies Act. Reuters reports that Wal-Mart is paying for lawyers for as many as 30 executives targeted by the DoJ over suspicion of bribery and other misconduct in Mexico, Brazil, China, and India.
Top 10 International Companies To Own In Right Now: Claim Post Resources Inc (CPS.V)
Claim Post Resources Inc., a junior exploration company, engages in the acquisition, exploration, and development of mineral resource properties in Canada. The company primarily focuses on exploring and developing base metals and gold properties located in the Abitibi Greenstone Belt Region near Timmins in Ontario, Canada. It holds a 100% interest in the Kamiskotia property comprising 1,195 claim units located in the Godfrey, Turnbull, Jamieson, Robb, Cote, Massey, Mountjoy, and Bonar townships; and a 100% interest in the Dayton Porcupine claims consisting of 49 patented claims in Deloro and Ogden townships, as well as has an option to earn up to 100% interest in the Racetrack Project comprising 103 claim units and 12 patented claims located in Ogden township. Claim Post Resources Inc. was founded in 2005 and is headquartered in Toronto, Canada.
Top 10 International Companies To Own In Right Now: Kips Bay Medical Inc.(KIPS)
Kips Bay Medical, Inc., a development stage medical device company, focuses on developing, manufacturing, and commercializing external saphenous vein support technology or eSVS MESH for use in coronary artery bypass grafting, or CABG surgery in the United States. Its eSVS MESH is nitinol meshes sleeve that, when placed over a saphenous vein graft during CABG surgery, is designed to improve the structural characteristics and long-term performance of the vein graft. The company was founded in 2007 and is based in Minneapolis, Minnesota.
Hot Bank Companies To Watch For 2014: Five Oaks Investment Corp (OAKS.N)
Five Oaks Investment Corp., incorporated on March 28, 2012, focused on investing in, financing and managing a leveraged portfolio of Agency and Non-Agency residential mortgage-backed securities, or RMBS, residential mortgage loans and other mortgage-related investments. The Company invests in both Agency RMBS and Non-Agency RMBS.
As of December 31, 2012, the Company�� portfolio consisted of Agency RMBS and Non-Agency RMBS. The Company is managed by Oak Circle Capital Partners LLC.
Top 10 International Companies To Own In Right Now: Golden Predator Royalty&Dev Co (GPD.TO)
Americas Bullion Royalty Corp. engages in the exploration and development of gold properties primarily in Yukon, Canada. Its principal projects include Brewery Creek, Grew Creek, and Clear Creek projects located in Yukon, as well as exploration landholdings comprising approximately 1,200,000 acres. It also has property interests in western Canada, the western United States, and Mexico. The company was formerly known as Golden Predator Corp. and changed its name to Americas Bullion Royalty Corp. in February 2013. Americas Bullion Royalty Corp. was founded in 2009 and is headquartered in Vancouver, Canada.
Top 10 International Companies To Own In Right Now: SodaStream International Ltd.(SODA)
SodaStream International Ltd. engages in the development, manufacture, and marketing of home beverage carbonation systems and related products. Its home beverage carbonation systems enable consumers to transform ordinary tap water into carbonated soft drinks and sparkling water. The company offers a range of soda makers; exchangeable carbon-dioxide (CO2) cylinders; beverage-grade CO2 refills; reusable carbonation bottles; and various flavors comprising fruit, carbonated soft drink, and enhanced flavors to add to the carbonated water. It also sells additional accessories for its products, including bottle cleaning materials and ice cube trays manufactured by third parties. The company sells its products under the SodaStream and Soda-Club brand names through approximately 50,000 retail stores in 42 countries, as well as through the Internet; and distributes its products directly in 12 countries and indirectly through local distributors in other markets. It operates in Europe , North and Central America, Israel, South Africa, Australia, New Zealand, and east Asia. The company was formerly known as Soda-Club Holdings Ltd. and changed its name to SodaStream International Ltd. in March 2010. SodaStream International Ltd. is headquartered in Airport City, Israel.
Advisors' Opinion:- [By Blake Bos]
In the following video, Motley Fool consumer-goods analyst Blake Bos tells investors about a new patent from Green Mountain Coffee Roasters (NASDAQ: GMCR ) , that may mean it's getting into the game of home soda machines, a space currently dominated by SodaStream (NASDAQ: SODA ) . Blake gives us a picture of the key things that will need to happen for Green Mountain to be successful in this endeavor, and tells us why he isn't necessarily worried about SodaStream just yet. In fact, for SodaStream, this could even have a positive effect.
Top 10 International Companies To Own In Right Now: Webjet Ltd(WEB.AX)
Webjet Limited, through its subsidiaries, operates as an electronic manager, marketer, and credit card merchant of travel and related services utilizing the Internet and other mediums. It offers airline tickets and travel packages to customers in Australia, New Zealand, Asia, the United States, and Europe. The company is based in Melbourne, Australia.
Top 10 International Companies To Own In Right Now: ABAXIS Inc.(ABAX)
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in veterinary or human patient-care setting to provide blood constituent measurements for clinicians worldwide. The company offers point-of-care blood chemistry analyzer, which consists of a compact portable analyzer and a series of single-use plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 14 tests on human patients and 13 tests on veterinary patients. It markets the blood analysis system under the Piccolo Xpress and Piccolo Classic names in the medical market; and under the VetScan VS2 and VetScan Classic names in the veterinary market. The company also provides VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments for veterinary applications. In addition, its products include VetScan VSpro, which assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluatio n of disseminated intravascular coagulation, hepatic disease, monitoring therapy, and the progression of disease states. Further, the company offers VetScan VSpro fibrinogen test to provide in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT 1 that delivers blood gas, electrolyte, basic blood chemistry, and hematology results. Additionally, its products comprise Canine Heartworm Rapid Test to detect dirofilaria immitis in canine whole blood, serum, or plasma; Canine Parvovirus Rapid Test Kit to detect canine parvovirus antigen in feces; and VetScan Giardia Rapid Test to detect giardiasis, a gastrointestinal infection caused by the protozoan parasite Giardia. Abaxis sells its products through direct sales force and independent distributors. The company was founded in 1989 and is headquartered in Union City, California.
Top 10 International Companies To Own In Right Now: Tribune Co (TRBAA.PK)
Tribune Company, incorporated on March 19, 1968, is a media and entertainment company engaged in newspaper publishing, television and radio broadcasting and entertainment through its subsidiaries. The Company�� operations are divided into two industry segments: publishing and broadcasting and entertainment. In publishing, the Company�� daily newspapers include the Los Angeles Times, Chicago Tribune, The Baltimore Sun, Sun Sentinel (South Florida), Orlando Sentinel, Hartford Courant, The Morning Call and Daily Press. The company�� broadcasting group operates 23 television stations, WGN America on national cable and Chicago�� WGN-AM.
Broadcasting
The Company�� broadcasting owns and operates 23 major-market television stations and reaches more than 80% of United States television households. The group is anchored by WGN America, which can be seen in more than 70 million United States households via cable and satellite services. 13 Tribu ne stations are affiliates of The CW. Seven are FOX affiliates.
Publishing
The Company�� newspapers include the Los Angeles Times and Chicago Tribune. Tribune Media Services specializes in entertainment listings and syndication, providing news and information for print, broadcast and interactive media.
Tribune Digital
Tribune Digital manages the operations of Tribune�� daily newspapers and their associated Websites, plus all aspects of the Company�� classified advertising operations, as well as Websites for Tribune�� TV stations. Its national classified sites include CareerBuilder.com, Cars.com and Apartments.com.
Top 10 International Companies To Own In Right Now: Telik Inc (TELK)
Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�� drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.
Clinical Product Development
TELINTRA is the Company�� lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. It has a mechanism of action and acts by inhibiting GST P1-1, an enzyme that is involved in the control of cellular growth and differentiation. Inhibition of GST P1-1 results in the activation of the signaling molecule Jun kinase, a regulator of the function of blood precursor cells. Preclinical tests show that TELINTRA is capable of causing the death or apoptosis of leukemic or malignant blood cells, while stimulating the growth and development of normal blood precursor cells. TELINTRA has been studied in Myelodysplastic Syndrome (MDS) using two formulations. A liposomal formulation was developed for intravenous administration of TELINTRA and was used in Phase I and Phase II studies in MDS patients. The results from the Phase II intravenous liposomal TELINTRA clinical trials demonstrated that TELINTRA treatment was associated with improvement in all three types of blood cell levels in patients with all types of MDS, including those in intermediate and high-risk groups. An oral dosage formulation (tablet) was subsequently developed and results from a Phase I study with TELINTRA tablets showed clinical activity and the formulation to be well tolerated. In June 2011, the Company initiated a Phase II clinical ! trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. '
The activity and safety profile of tablet formulation allowed the Company to complete a Phase II trial of TELINTRA tablets in MDS. The primary objective of the Phase II TELINTRA tablet study was to determine the efficacy of TELINTRA. A multivariate logistic regression analysis was conducted to identify MDS disease prognostic factors associated with erythroid improvement response rates, including prior MDS treatment, age, gender, the international prognostic scoring system (IPSS), risk, Eastern Cooperative Group performance status, years from MDS diagnosis, MDS World Health Organization subtypes, anemia only versus anemia plus other cytopenias, dose schedule and starting dose. Results from this study show that TELINTRA is the first GSTP1-1 enzyme inhibitor shown to cause clinically reductions in red blood cell transfusions, including transfusion independence in low to intermediate-1 risk MDS patients, as well as improvement in platelet count and white blood cell levels in certain patients. TELINTRA, administered orally twice daily, appeared to be convenient and flexible for chronic treatment administration.
TELCYTA is a small molecule drug product candidate that the Company is developed for the treatment of cancer. TELCYTA binds to GST. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer. Results from these clinical trials indicate that TELCYTA monotherapy was generally well-tolerated, with mostly mild to moderate side effects, particularly when compared to the side effects and toxicities of standard chemotherapeutic drugs. When TELCYTA was evaluated in combination with standard chemotherapeutic drugs, the tolerability of the combinations was similar to that expected of each! drug alo! ne.
Clinical activity including objective tumor responses and/or disease stabilization was reported in the TELCYTA Phase II trials; however, TELCYTA did not meet its primary endpoints in the Phase III studies. Positive results from a Phase I-IIa multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with non-small cell lung cancer, or NSCLC, were published in a peer reviewed publication. Clinical data demonstrated positive results of TELCYTA in combination with carboplatin and paclitaxel in the treatment of first-line lung cancer followed by TELCYTA maintenance therapy. As of December 31, 2011, the Company had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphoma, and multiple myeloma.
Preclinical Drug Product Development
The Company has a small molecule compound, TLK60404, in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Aurora kinase is a signaling enzyme whose function is required for cancer cell division, while VEGF plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. These lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR kinase. A development drug product candidate, TLK60404, has been selected.
The Company, using its TRAP technology has discovered TLK60357, a novel, potent small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. This compound demonstrates potent broad-spectrum anticancer activity against a number of human cancer cells. This compound also displays oral efficacy in multiple, standard preclinical models of cancer. TLK60596, a potent VG! FR kinase! inhibitor, blocks the formation of new blood vessels in tumors. Oral administration of TLK60596 to animal models of human colon cancer reduced tumor growth.
No comments:
Post a Comment